Loading
AT
Audentes Therapeutics, Inc. Stock: price and insider trades · United States
Audentes Therapeutics, Inc.: what insiders have been doing
Audentes Therapeutics, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). No insider at Audentes Therapeutics, Inc. has published a filing in the past twelve months. The most recent one dates from 15 January 2020.
The full history, which starts in 2018, counts no purchases against 54 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
136
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€11M
54 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 15 January 2020
Declarations136 total
32,705 shares@ US$60.0087.7% of flowCommon StockSEC:0001209191-20-003431:0
1,500 shares@ US$60.00100.0% of flowCommon StockSEC:0001209191-20-003427:0
24,584 shares@ US$60.0082.1% of flowCommon StockSEC:0001209191-20-003426:0
183,384 shares@ US$60.0081.6% of flowCommon StockSEC:0001209191-20-003437:0
26,919 shares@ US$60.0084.8% of flowCommon StockSEC:0001209191-20-003433:0
89,695 shares@ US$60.00100.0% of flowCommon StockSEC:0001209191-20-003435:0
265,799 shares@ US$60.0070.6% of flowCommon StockSEC:0001209191-20-003430:0
13,678 shares@ US$60.003.6% of flowCommon StockSEC:0001209191-20-003430:1
32,343 shares@ US$60.008.6% of flowCommon StockSEC:0001209191-20-003430:2
3,555 shares@ US$60.000.9% of flowCommon StockSEC:0001209191-20-003430:3
104,439 shares@ US$60.0044.7% of flowCommon StockSEC:0001209191-20-003428:0
261,458 shares@ US$60.0048.4% of flowCommon StockSEC:0001209191-20-003434:0
171,814 shares@ US$60.0031.8% of flowCommon StockSEC:0001209191-20-003434:1
64,751 shares@ US$0.780.2% of flowCommon StockSEC:0001209191-20-003110:1
74,297 shares@ US$2.190.5% of flowCommon StockSEC:0001209191-20-003110:2
11,824 shares@ US$9.500.3% of flowCommon StockSEC:0001209191-20-003110:3
11,666 shares@ US$15.260.5% of flowCommon StockSEC:0001209191-20-003110:4
144,669 shares@ US$2.763.0% of flowCommon StockSEC:0001209191-20-003111:0
6,219 shares@ US$15.260.7% of flowCommon StockSEC:0001209191-20-003111:1
12,500 shares0Common StockSEC:0001209191-20-003110:0
10,000 shares@ US$59.602.7% of flowCommon StockSEC:0001209191-19-062016:0
1,000 shares@ US$59.600.3% of flowCommon StockSEC:0001209191-19-062016:1
8,681 shares@ US$59.373.8% of flowCommon StockSEC:0001209191-19-060731:0
41,321 shares@ US$2.760.8% of flowCommon StockSEC:0001209191-19-060731:1
21,458 shares@ US$59.379.4% of flowCommon StockSEC:0001209191-19-060731:2
25 of 136 declarations
About Audentes Therapeutics, Inc.
Audentes Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for rare diseases. It is listed on NASDAQ under the ticker ATRA.
